Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Bristol-Myers Squibb Co., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Short-term debt obligations 6.25 3.28 5.99 3.23 2.92 4.40 2.17 4.94 7.30 4.53 4.57 2.40 1.58 1.98 2.86 3.76 2.99 2.57 0.99 0.99 1.09
Accounts payable 3.57 3.42 3.08 3.28 3.39 3.14 2.64 2.87 2.86 2.70 2.43 3.26 2.64 2.29 1.94 2.23 2.37 1.88 3.29 3.63 5.67
Other current liabilities 16.25 16.69 16.64 15.04 13.94 15.07 14.46 13.03 11.99 12.78 12.35 11.49 11.19 11.84 11.50 12.30 9.51 9.63 13.98 12.98 18.61
Current liabilities 26.07% 23.39% 25.71% 21.55% 20.24% 22.61% 19.28% 20.84% 22.15% 20.00% 19.35% 17.14% 15.41% 16.10% 16.30% 18.29% 14.88% 14.09% 18.26% 17.60% 25.38%
Deferred income taxes 0.45 0.36 0.44 0.80 1.66 2.24 2.93 3.02 3.70 4.12 4.47 4.45 4.66 4.56 4.71 4.81 5.05 4.97 0.00 0.00 0.00
Long-term debt, excluding current portion 49.97 38.52 35.21 37.07 37.21 36.21 37.65 36.97 36.35 36.23 35.78 38.36 39.58 40.80 32.95 32.68 33.14 33.39 42.47 44.29 16.18
Other non-current liabilities 6.80 6.75 6.80 6.31 7.07 6.81 6.81 6.62 7.09 6.71 6.78 6.77 6.84 6.56 6.03 5.84 8.28 7.77 8.36 8.82 14.47
Non-current liabilities 57.22% 45.62% 42.45% 44.19% 45.94% 45.25% 47.39% 46.61% 47.14% 47.06% 47.03% 49.58% 51.08% 51.92% 43.69% 43.33% 46.47% 46.13% 50.82% 53.12% 30.65%
Total liabilities 83.29% 69.02% 68.16% 65.74% 66.18% 67.86% 66.66% 67.46% 69.29% 67.06% 66.38% 66.72% 66.49% 68.03% 59.99% 61.62% 61.34% 60.22% 69.09% 70.72% 56.03%
Preferred stock 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock 0.29 0.31 0.32 0.31 0.31 0.30 0.30 0.29 0.28 0.27 0.26 0.26 0.26 0.25 0.23 0.23 0.23 0.22 0.38 0.40 0.63
Capital in excess of par value of stock 46.10 48.01 49.14 48.45 47.88 46.65 45.78 44.22 42.47 40.58 39.94 39.77 39.00 37.41 35.40 34.70 33.46 33.64 3.84 3.90 6.04
Accumulated other comprehensive loss -1.41 -1.62 -1.41 -1.48 -1.45 -1.32 -0.86 -0.99 -1.19 -1.16 -1.28 -1.37 -1.37 -1.55 -1.35 -1.21 -1.20 -1.17 -2.55 -4.75 -7.59
Retained earnings 15.79 30.23 30.92 29.36 28.18 26.34 25.13 24.13 23.24 21.79 20.40 20.01 19.75 17.96 25.82 24.65 25.27 26.53 63.65 65.03 100.79
Cost of treasury stock -44.12 -45.99 -47.20 -42.44 -41.16 -39.89 -37.08 -35.17 -34.15 -28.60 -25.77 -25.45 -24.19 -22.14 -20.14 -20.03 -19.15 -19.51 -34.60 -35.48 -56.18
Total BMS shareholders’ equity 16.65% 30.93% 31.77% 34.20% 33.75% 32.08% 33.27% 32.48% 30.65% 32.88% 33.56% 33.22% 33.45% 31.92% 39.96% 38.33% 38.61% 39.71% 30.73% 29.09% 43.69%
Noncontrolling interest 0.06 0.06 0.07 0.06 0.07 0.06 0.06 0.06 0.06 0.05 0.06 0.06 0.06 0.05 0.06 0.05 0.05 0.08 0.18 0.18 0.28
Total equity 16.71% 30.98% 31.84% 34.26% 33.82% 32.14% 33.34% 32.54% 30.71% 32.94% 33.62% 33.28% 33.51% 31.97% 40.01% 38.38% 38.66% 39.78% 30.91% 29.28% 43.97%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Bristol-Myers Squibb Co. current liabilities as a percentage of total liabilities and equity decreased from Q3 2023 to Q4 2023 but then increased from Q4 2023 to Q1 2024 exceeding Q3 2023 level.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co. non-current liabilities as a percentage of total liabilities and equity increased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Bristol-Myers Squibb Co. total liabilities as a percentage of total liabilities and equity increased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.
Total BMS shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Bristol-Myers Squibb Co. total BMS shareholders’ equity as a percentage of total liabilities and equity decreased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.